10-2011

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach

Edward Yu  
*The University of Western Ontario*

Craig Lewis  
*The University of Western Ontario*

Ana Luisa Trejos  
*The University of Western Ontario*

Rajni V. Patel  
*The University of Western Ontario*

Richard A. Malthaner  
*The University of Western Ontario*

Follow this and additional works at: [https://ir.lib.uwo.ca/oncpub](https://ir.lib.uwo.ca/oncpub)

Part of the [Electrical and Computer Engineering Commons](https://ir.lib.uwo.ca/ececommons), [Medical Biophysics Commons](https://ir.lib.uwo.ca/medbiophyscommons), and the [Oncology Commons](https://ir.lib.uwo.ca/oncologycommons)

Citation of this paper:

[https://ir.lib.uwo.ca/oncpub/77](https://ir.lib.uwo.ca/oncpub/77)
Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach

Edward Yu *,1, Craig Lewis1, Ana Luisa Trejos2,3, Rajni V. Patel2,3, and Richard A. Malthaner1,2

1The University of Western Ontario, London Health Science Center, Division of Radiation Oncology, 790 Commissioners Road East, London, Ontario, N6A 4L6, Canada
2Canadian Surgical Technologies and Advanced Robotics, Lawson Health Research Institute, 339 Windermere Road, London, Ontario, N6A 5A5, Canada
3Department of Electrical and Computer Engineering, The University of Western Ontario, 1151 Richmond Street North, London, ON, N6A 5B9, Canada

Abstract: New technological concepts have been evolving to manage the relative poor prognosis of lung cancer. Brachytherapy is becoming an option for both unresectable and early resectable lung cancer. Three-dimensional ultrasound (US) of lung tumours and image-guided minimally invasive robotics-assisted brachytherapy are feasible for dosimetry planning and management of lung tumours. The present article reviews the current knowledge of lung brachytherapy and discusses its potential in future management of lung cancer.

Keywords: Brachytherapy, lung tumour, minimally invasive, robotics-assisted surgery and therapy.

INTRODUCTION

Lung cancer is the leading cause of cancer death in men, and has surpassed breast cancer as the most frequent cause of death in women [1]. Surgical resection is the treatment of choice, but only one third of patients who present with early disease are eligible for a curative resection [2]. Open surgery provides ready access and optimal visualization of body cavities, however, it has a higher rate of morbidity compared to minimally invasive techniques. Other options need to be developed. Brachytherapy is a form of radiation therapy delivered by the direct placement of a radioactive source into a tumour or tumour bed. It provides an option that avoids major surgery, chemotherapy, and is not susceptible to the uncertainty of tumour motion while the patient receives external beam radiation. It also avoids conventional multiple external beam radiation fractions that occur over several weeks. Brachytherapy also has theoretical advantages including: i) it is easily adapted to the shape and size of tumour, ii) it delivers a higher tumour dose compared to external beam irradiation, and iii) the delivered radiation dose decreases rapidly outside the treated tumour volume, significantly sparing the normal tissue in the tumour vicinity.

LUNG CANCER BRACHYTHERAPY

Endobronchial and/or intraoperative lung brachytherapy is effective and has a good curative potential in patients with localized tumours of small to moderate size, well defined and easily accessible. Large tumours, multiple lesions, or the presence of lymph node metastases precludes curative treatment by brachytherapy. In selected cases, quick and effective palliation may be obtained by an endobronchial outpatient procedure.

Brachytherapy techniques and approaches can be tailored to the clinical situation and can be administered over a very short period of time (high dose rate), or over a protracted period of time (low dose rate). Table 1 shows the commonly used isotopes in brachytherapy.

There are two common brachytherapy techniques for lung cancer: Endobronchial Brachytherapy and Interstitial Brachytherapy. The details of these two techniques are discussed below.

Endobronchial Brachytherapy

Endobronchial treatment is the most common lung brachytherapy technique. Radiation therapy is delivered from within the trachea or bronchus lumen by placement of one or two afterloading applicators. The applicators, sometimes referred to as catheters, typically have a 5 or 6 French external diameter. A guidewire is often used to pass directly through the operating channel of a fibre optic bronchoscope and be threaded through the involved airway. Care must be taken to slowly advance the applicator over the guidewire, preferably under direct visual or fluoroscopic control. After placement of the brachytherapy catheter, the bronchoscope is removed and “dummy” seeds (an inactive strand of radiopaque marker pellets) are inserted within the applicator. An orthogonal set of chest radiographs (anterior-posterior and cross-table lateral) are obtained. The target is identified on the films using the visual information obtained that day by the bronchoscopist combined with previous radiological or bronchoscopic findings. The distal extent of the tumour cannot always be visualized by the bronchoscopist and must often be estimated from previous computerized tomography scans, chest radiographs, etc. Brachytherapy is delivered to the endobronchial tumour length with a 1–2 cm proximal and distal margin. The dummy seeds are then removed from the catheter and replaced with an inner applicator with radiation source of either Low Dose Rate (LDR) or High...
Dose Rate (HDR) inner applicator. HDR remote afterloading machines contain a microprocessor that controls the transfer of the source down the flexible inner applicator to the specified region, and withdraws it automatically into the machine when treatment is complete. Treatment is delivered in a shielded room where the patient and the patient’s vital signs and oxygen saturation can be monitored from outside the room with the use of video equipment. The remote afterloading treatment can be interrupted at any time if necessary.

**Interstitial Brachytherapy**

Several investigators have described the technical aspects of permanent interstitial brachytherapy, the placement of radioactive source into the tumour or target region where no lumen exists [3–7]. This can be accomplished intraoperatively, transbronchially, or percutaneously. Isotopes such as Iodine (I-125), Palladium (Pd-103) and Gold (Au-198) which have low energy gamma rays, small physical size, and short half-lives are often used. Mick applicators are commercially available to insert the seeds manually one by one into the target region. However, the risk of subsequent seed movement has led many brachytherapists to suggest, depending on the clinical situation, that seeds be in the form of a strand with a Vicryl® carrier which can be woven into a Dexon® mesh and secured to the tumour bed [5]. Nori et al. [5] have described the intraoperative technique of sandwiching iodine seeds between sheets of Gelfoam and then securing these in place with Dexon®/Vicryl® mesh. In their experience, the seeds have remained in site despite the fact that the mesh and Gelfoam are absorbed within the surrounding tissues within 6–8 weeks.

Brachytherapy can be given in either HDR or in LDR as presented below. A review the clinical results of brachytherapy is also presented.

**HDR Brachytherapy**

HDR brachytherapy has been defined as brachytherapy capable of delivering more than 12 Gy/h (>0.2 Gy/min) [8]. The isotopes most commonly used include Cobalt (Co-60), Caesium (Cs-137), and Iridium (Ir-192). Endobronchial HDR brachytherapy uses a flexible bronchoscope to place an intraluminal treatment applicator at the location of the tumour to provide higher radiation dose at the center of the tumour than at the periphery. This reduces the effect of the radiation on the surrounding tissue [9]. HDR brachytherapy has been used as an alternative to, and in combination with, external beam radiation therapy for palliation of symptoms such as dyspnea, cough, chest pain, and hemoptysis in nonsmall cell lung cancer (NSCLC) [10]. Quality of life assessment in HDR has been reported in randomized trials including Langendijk et al. [11] the European Organization for Research and Treatment of Cancer (EORTC) general questionnaires, Sur et al. [12,13] the National Cancer Institute Common Toxicity Criteria, Stout et al. [14] Rotterdam Symptom Checklist and Hospital Anxiety and Depression scale. In general HDR relieves and improves symptoms of dyspnea, atelectasis, and chest pain. In particular HDR is most valuable in patients previously treated with external beam radiation therapy and symptomatic for recurrent disease due to endobronchial obstruction. The general recommended dose for HDR in symptom control is 1000 cGy at 1 cm from central axis given in a single fraction, with 2 cm proximal and distal margin [10]. Most tumours either decreased in size or there was a reduction in pain. However, complications such as pneumothorax, and hemoptysis have been described [10].

An electromagnetic navigated bronchoscopic approach to a small peripheral tumour has recently been described by Harms et al. [15]. A single patient with medically inoperable NSCLC in the right upper lobe was treated with external-beam radiotherapy (50 Gy) and navigated endoluminal brachytherapy (15 Gy). Bronchoscopy was performed with an electromagnetic navigation using a microsensor mounted on the tip of a dedicated catheter placed within the working channel of a bronchoscope. Endobronchial ultrasound (EBUS) was performed to confirm the exact position in the center of the lesion. HDR brachytherapy (370 GBq Ir-192) was applied. Complete remission was found during follow-up (12 months). HDR brachytherapy has also been delivered to lung cancers using a percutaneous route [16–20].

<table>
<thead>
<tr>
<th>Isotopes</th>
<th>T1/2</th>
<th>γ-Ray (MeV)</th>
<th>β-Ray (Avg.MeV)</th>
<th>T(R/mCi/hr@1cm)</th>
<th>HVL (cmPb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>60Co</td>
<td>5.26y</td>
<td>1.25</td>
<td>0.093</td>
<td>13.07</td>
<td>1.03</td>
</tr>
<tr>
<td>90 Sr</td>
<td>28y</td>
<td>-</td>
<td>0.196</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>98mTc</td>
<td>6.03h</td>
<td>0.141</td>
<td>0.014</td>
<td>0.6</td>
<td>-</td>
</tr>
<tr>
<td>103Pd</td>
<td>16.97d</td>
<td>0.022</td>
<td>-</td>
<td>1.48</td>
<td>0.001</td>
</tr>
<tr>
<td>125I</td>
<td>59.4d</td>
<td>0.028</td>
<td>0.036</td>
<td>1.33</td>
<td>0.003</td>
</tr>
<tr>
<td>131I</td>
<td>8.06d</td>
<td>0.08-0.723</td>
<td>0.192</td>
<td>2.24</td>
<td>0.3</td>
</tr>
<tr>
<td>137Cs</td>
<td>30.0y</td>
<td>0.662</td>
<td>0.186</td>
<td>3.28</td>
<td>0.6</td>
</tr>
<tr>
<td>192Ir</td>
<td>74.0d</td>
<td>0.36</td>
<td>0.181</td>
<td>4.6</td>
<td>0.26</td>
</tr>
<tr>
<td>198Au</td>
<td>2.7d</td>
<td>0.412</td>
<td>0.315</td>
<td>2.38</td>
<td>0.3</td>
</tr>
<tr>
<td>226Ra</td>
<td>1604y</td>
<td>1.03</td>
<td>-</td>
<td>8.25</td>
<td>0.8</td>
</tr>
</tbody>
</table>

T – Exposure rate constant; T1/2 – Half-life; HVL- Half value layer; y-year, d-day, h-hour.
and coworkers [19] reported a pilot study of 30 patients with interstitial HDR brachytherapy. In their study cohort the maximum tumour size was 4 cm and the brachytherapy catheter was positioned under CT fluoroscopy. A single fraction of 20 Gy was delivered to the tumour. Although the follow up was short (median 5 months) local tumour control was 97%. CT guided interstitial brachytherapy was safe.

Brachytherapy has been used by several investigators as a boost either before, during or after external beam radiation in the definitive treatment of unresectable NSCLC. The experience of HDR brachytherapy boost is extensive in the literature [21–27]. Patients selected for definitive external beam radiation and a brachytherapy boost were usually medically fit patients with centrally located stage IIIA or IIIB tumours, without weight loss in 6 months leading up to diagnosis. External beam radiation dose ranged from 50–70 Gy with HDR boost of 2.7–10 Gy per fraction at 1–5 fractions over a 1–2 week fraction interval. Response to brachytherapy was assessed by bronchoscopy 1–3 months from completion of treatment. As expected, initial patient performance status, tumour size and stage, and radiation dose are important predictors of outcome [22, 26, 28]. Aygun and colleagues [22] observed that response rates favour patients with tumours not visible radiographically. Higher combined doses of brachytherapy and external beam radiation have been associated with an increased endobronchial response. No complications were seen in patients treated to a dose of 70 Gy, as compared to a 24% complication rate seen in patients receiving more than 85 Gy [27]. Common complications are hemoptysis, bronchial stenosis, and bronchitis, with tracheoesophageal fistula being less commonly reported in the literature. Differentiating treatment complications from tumour progression is often challenging as autopsies have been done in only a small proportion of patients undergoing brachytherapy. For tumours in the mainstem or upper lobe bronchus, there appears to be an increased frequency of hemorrhage for right-sided (25%) as opposed to left-sided lesions (25% and 10%), perhaps due to the proximity of the treatment catheter to the pulmonary artery [22].

**LDR Brachytherapy**

LDR brachytherapy is another form of radiation therapy with dose rates ranging from 0.1 cGy/hr to 50 cGy/hr. The radioisotopes most commonly used include Iodine (I-125), Palladium (Pd-103) and gold (Au-198), and when placed inside titanium shells are called seeds. They can be in the form of individual seeds or joined together to form a strand. The overall size of the seed can vary slightly depending on the application.

Hilaris and Martini reviewed the Memorial Sloan-Kettering Cancer Center experience in over 1,000 patients that received intraoperative (LDR) brachytherapy via an open thoracotomy [20]. The use of interstitial brachytherapy as potential curative and palliative treatment of superior sulcus tumours have been reported extensively [29–31]. Results of 129 patient case series have been reported by the Memorial Sloan-Kettering Cancer Center with superior sulcus tumour treated with I-125 for permanent implantation or temporary implantation of Ir-192. The overall survival of this series was encouraging with 25% survival rate at 5 years favouring patients with adenocarcinomas, negative mediastinal involvement, preoperative radiation therapy followed by surgery. Radiation toxicity includes mild dysphagia for patients who received mild dose of preoperative radiation therapy. Selective intraoperative brachytherapy has been reported by Armstrong et al. [32]. In their case series of 10 patients receiving intraoperative brachytherapy for residual disease, in spite of the advanced disease in the brachytherapy group, actual progression free survival at 2 years and 5 years was 66% and 55% respectively. Intraoperative LDR lung brachytherapy alone or in combination with other local and systemic therapies suggest that a subgroup of patients with gross or microscopic disease left in the thorax after incomplete resection or biopsy only, can be controlled locally [33].

Interstitial brachytherapy is not used frequently in clinical practice. This may be due to difficulty in gaining expertise with interstitial techniques, as compared to external beam treatment planning or even endobronchial brachytherapy. Endobronchial brachytherapy is more widely practiced in many cancer centers [10, 34]. Brachytherapy-related complications have been graded and management has been proposed [25, 35].

Brachytherapy-related hemoptysis has been graded as massive (fatal) or not massive, and management is the same as hemoptysis from other causes. Treatment includes bed rest, codeine, fluid replacement, avoidance of anticoagulants, selective lung insulation and bronchial artery embolization. A brachytherapy related bronchitis grading system to enable comparison of complication between various dose-fractionation regimens has been proposed by Speiser and Spratling [25] and management is summarized in Table 2.

**INTERSTITIAL BRACHYTHERAPY – A CHALLENGING PROCEDURE**

Interstitial brachytherapy allows more precise delivery of radiation and easier adaptation to the tumour shape than is possible with external radiation [20, 36], and a higher dose can be delivered to the tumour volume with less damage to the normal lung. The seeds are implanted into cancerous tissue using long and hollow needles, which have small outer diameters and at least one sharp end to allow penetration through the tissue. The seeds are manually loaded into the needle barrel and are spaced from each other by one or more inert spacers that are implanted together with the seeds. A small amount of bone wax is placed on the tip of the implant needles to prevent the seeds from falling out and to prevent the tissue from entering the hollow needle. A stylet inserted in the needle behind the last seed is used to release the bone wax and drop the seeds.

During the brachytherapy procedure, the goal is to implant the seeds into the tumour such that they are uniformly distributed in a particular pattern selected to ensure that the tumour receives the appropriate dose. In general, a series of aligned seeds is introduced with each insertion of the needle. To achieve this goal, each needle must be accurately inserted into the tissue following a particular path and reaching a specified depth. Accurate placement is required to avoid over-radiated and under-radiated areas, and to ensure that all the seeds are located.
I. the causes for seed misplacement are as follows: significant areas of over-dosage and under-dosage. Some of the seeds, since small deviations in seed alignment can create procedure, this challenge translates into accurately placing and minimize side effects [37]. During a lung brachytherapy planning and delivery is required in order to optimize results treatment is very complex, careful consideration of the achieving an accurate dosage of radiation. Since the entire prostate using between 20 and 25 needles.

This procedure is commonly performed in the prostate, for which coordinate grids are often used to guide the needle insertion in order to improve the accuracy of needle placement, while real-time ultrasound images are used to guide the needles to the desired depth. In a common prostate brachytherapy procedure, 80–100 seeds are implanted into the prostate using between 20 and 25 needles.

The biggest challenge in delivering radiation therapy is achieving an accurate dosage of radiation. Since the entire treatment is very complex, careful consideration of the planning and delivery is required in order to optimize results and minimize side effects [37]. During a lung brachytherapy procedure, this challenge translates into accurately placing the seeds, since small deviations in seed alignment can create significant areas of over-dosage and under-dosage. Some of the causes for seed misplacement are as follows:

I. Difficulty in accessing the surgical site due to the presence of bone structures (rib cage), major nerves, or blood vessels. Significant clinical expertise is needed to properly access the surgical site [38].

II. Difficulty in locating the needle prior to the penetration, and in achieving the proper penetration depth.

III. During needle barrel retraction, difficulty in holding of the stylet stable relative to the needle. Small unintended movements of the stylet relative to the barrel can result in inaccurate seed placement and a reduction in the effectiveness of the treatment.

IV. Changes in tissue location and size between dose planning and seed implantation [39].

V. Patient movement during the procedure due to tissue shift, breathing, heartbeat, or swelling of the organs.

Furthermore, in traditional brachytherapy procedure the surgical personnel are exposed to the radiation source for a large amount of time. Manual insertion of the needles can take a long time, since it sometimes requires as many as 20 insertions prior to achieving accurate placement.

The use of LDR encapsulated I-125 seeds with its 60 days half-life and low energy photon make interstitial brachytherapy more practical. It greatly reduces the radiation outside of the treatment volume and minimizes the medical and nursing staff exposure. However, the intraoperative radiation exposure to the surgeon and radiation oncologist and the need for a large open thoracotomy with only a modest survival advantage has hindered its clinical acceptance.

There is only limited experience with LDR interstitial brachytherapy under bronchosopic, fluoroscopic and CT guidance [2, 20, 40–42]. Although the CT-guided percutaneous approach is feasible, it is limited to small and soft tumours in the periphery of the lung, and the optimum radiation dose distribution frequently cannot be achieved due to the bony structures in the chest wall that inhibits precise seed implantation. The risk of injury to proximal mediastinal structures, bleeding, and lung collapse, also limits this technique to only small tumours adjacent to the chest wall.

**ROBOTICS-ASSISTED MINIMALLY INVASIVE THORACIC SURGERY**

Minimally invasive surgery (MIS) employs the use of instruments through small incisions in the patient’s chest or abdomen to remove cancers. The procedure relies on endoscopic video images for guidance, and the surgeon for instrument manipulation. Procedure-related intraoperative complications can be dealt with immediately. Compared with a thoracotomy, MIS or video-assisted thoracoscopic surgery (VATS) offers patients a shorter length of hospital stay, less pain, and a quicker recovery, without compromising the adequacy of the operation [43, 44]. Thousands of VATS lobectomies have been performed since it was pioneered in 1992, but currently most lobectomies are still performed via a thoracotomy. Although most lobectomies could be performed as VATS, less than 5% are currently performed this way due to limitations of minimal access, restricted manoeuvrability of instruments, and impaired two-dimensional (2D) visualization. The techniques are difficult to learn and therefore not used as often.

Surgical robots have been shown to improve MIS efficiency by providing superior three-dimensional (3D)

---

**Table 2. Grading of Radiation Bronchitis and Management**

<table>
<thead>
<tr>
<th>Grading</th>
<th>Radiation Bronchitis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I</td>
<td>Mild mucosal inflammatory response with swelling, characterized by a thin, whitish, circumferential membrane. No significant luminal obstruction.</td>
<td>Observation</td>
</tr>
<tr>
<td>Grade II</td>
<td>White fibrinous membrane with exudation causing systems such as cough and/or obstructive problems</td>
<td>Steroids-oral and/or aerosol Fluconazole Saline-diluted bronchodilators Narcotic cough suppressants</td>
</tr>
<tr>
<td>Grade III</td>
<td>Severe inflammatory response with marked membranous exudate. Multiple debridement or other interventions required to reestablish full lumen of airway.</td>
<td>Balloon or bougie dilatation Laser photoresection Debridement Stents</td>
</tr>
<tr>
<td>Grade IV</td>
<td>Greater degree of fibrosis with resulting circumferential stenosis leading to a decrease in luminal diameter.</td>
<td>Same as in Grade III</td>
</tr>
</tbody>
</table>
magnification, enhanced dexterity, and improved precision by tremor filtration and motion scaling [45–48]. To the surgeon, surgical robots also offer improved ergonomics, instrument dexterity during VATS, and the opportunity to operate via telesurgery at a safer distance from the radioactive source [49]. Surgical use of robotics, or computer-assisted surgical systems (CAS), has evolved over the last 10 years for the treatment of chest diseases, however, significant development has really only occurred in the last 3 to 4 years. Moreover, because of this modest experience, robotic thoracic procedures currently take more time than non-robotic cases and, thus, are more expensive. The surgical learning curve appears to be steep, especially for the more complex procedures [50]. As surgeons gain greater experience and the complexity and cost of the equipment are reduced, we should expect to see greater use of CAS in thoracic surgery.

The ZEUS® surgical system was the world’s first and only telesurgical robotic platform able to provide surgical care at a distance. It had the potential to interface with surgeons in any part of the world and beyond. It was an ergonomically optimal environment that interfaced with a networked operating room and surgical devices. It was developed and manufactured by Computer Motion, Inc. Computer Motion merged with its competitor, Intuitive Surgical, Inc. and ZEUS robotic platform was replaced by the da Vinci® platform.

The da Vinci Surgical System combines superior 3D visualization along with greatly enhanced dexterity, precision, and control, in an intuitive, ergonomic interface with breakthrough surgical capabilities [46–48, 51]. By enhancing surgical capabilities, the robots reduce trauma to the body, reduce blood loss and need for transfusions, decrease post-operative pain and discomfort, lower the risk of infection, decrease hospital stay, allow for faster recovery and return to normal daily activities, reduce scarring, and improve cosmesis. The robots also allow the surgeon to perform minimally invasive procedures more safely, by allowing immediate access to vital structures and the ability to repair injuries that may occur during the brachytherapy procedure.

ADJUVANT BRACHYTHERAPY FOR LUNG CANCER

The recent increase in MIS has also renewed an interest in the role of adjuvant brachytherapy for lung cancer [52–59]. Following resection of small lung tumours (T1N0), intraoperative I-125 seeds have been implanted with Vicryl® mesh along the resection margins [52, 53, 57]. The technique appears to be safe and appears to reduce local tumour recurrence rates, but long-term results are required. Pisch et al. have reported on the ability of da Vinci system to suture in brachytherapy seeds into a porcine lung [56]. MIS wedge resections were performed in the upper and lower lobes. Dummy I-125 seeds embedded in absorbable sutures were sewn into the resection margin with the aid of the da Vinci system without complications. The robotic technology allowed direct placement of radioactive seeds into the resection margin by endoscopic surgery. This renewed enthusiasm for lung brachytherapy has resulted in a multi-institutional randomized phase III study of sublobar resection versus sublobar resection plus brachytherapy in high-risk patients with nonsmall cell lung cancer sponsored by the American College of Surgeons Oncology Group (ACOSOG 4032) [60]. This study is now closed accrual and results are pending.

It is believed that earlier detection of lung cancer should translate into more effective treatment. Lung cancer screening has been revived with various reports showing an advantage of low-dose CT over chest radiographs in detecting smaller size tumours and at an earlier stage [61]. Studies have found that eighty percent of all the tumours found were of stage I, with an estimated 8-year cure rate for resected lung cancers of 95% [62, 63]. This suggests that a higher proportion of deaths from lung cancer can be prevented by CT screening followed by early resection [63, 64]. The gold standard therapy for NSCLC is a lobectomy, while lesser resections are reserved as a compromise operation for high-risk patients [64, 65]. Earlier studies have suggested that sublobar resections for stage I tumours are complicated by increased locoregional recurrence rates [64, 66]. The increased identification of small NSCLC tumors by CT scan is leading many surgeons to question the appropriateness of lobectomy for these tumors. There is an increasing interest by many surgeons to use sublobar resection as the new standard for patients with small peripheral lung cancers [67]. Intentional sublobar resection for small lung cancers (T1N0) has been performed using minimally invasive techniques with equivalent results [68–74]. Recently, intraoperative brachytherapy on the resection staple line has been shown to significantly decrease the local recurrence rates associated with these limited resections [52, 54, 55, 57, 59]. Our experience with intraoperative brachytherapy reveals this technique can achieve considerable lung volume sparing for irradiation to normal tissue with less than 2% lung volume receiving 20 Gy1 (Fig. 1). Future directions in the management of early lung cancer will include MIS surgery combined with brachytherapy.

ROBOTICS-ASSISTED MINIMALLY INVASIVE BRACHYTHERAPY FOR LUNG CANCER

The future of lung cancer therapy may include the placement of individual brachytherapy seeds minimally invasively into lung cancers using a robotics-assisted brachytherapy seed delivery system. The prerequisites for such an approach are: i) a method to localize the tumour intraoperatively; ii) a means of tracking and guiding the needle in real time; iii) 3D images of the tumour from which the dosimetry will be planned (based on the tumour contours); and iv) a brachytherapy seed delivery device for the robot. Here we shall discuss the prerequisites of the robotics-assisted brachytherapy approach.

Lung Tumour Localization

For minimally invasive brachytherapy to be performed in the lung, it is imperative that some form of image guidance be incorporated for instrument tracking and tumour localization. Tumours that are deep within the lung cannot be seen with the thoracoscope. The procedure is performed

---

through small incisions making it impossible to palpate the nodules manually [75]. Current tumour localization techniques include methylene blue staining and the insertion of a hook wire [76-81]. These methods have been found to be cumbersome, have a high failure rate, and increase medical risks and litigation [82-84]. A method that can reliably localize lung nodules intraoperatively during a minimally invasive procedure is needed. Although lung tumours may be readily seen using CT imaging, CT scanners are not available in operating rooms for intraoperative use and there is often a delay of several months between a preoperative CT scan and the actual surgical procedure. From a global perspective, intraoperative ultrasound imaging appears to be the modality of choice. Ultrasound does not expose the patient to radiation as a CT does, and it can achieve real-time dependable dose plans for the delivery of brachytherapy. MIS ultrasound probes are now available from many manufacturers, enabling its use in guiding minimally invasive thoracic surgeries.

**Needle Tracking and Guidance**

Much effort has been put into overlaying real-time navigation information into preoperative information to serve as image guidance during procedures. A tracking device can be attached to the tool and its position displayed on the preoperative image (e.g. MRI, PET, CT). Kevin Cleary’s group at Georgetown University has developed a
system for surgical assistance incorporating magnetic tracking and CT image overlay for targeting internal organs such as the liver [85]. Roeddigcr’s group in Germany [86] has studied virtual reality image overlays for brachytherapy. Their work uses preoperatively acquired image data that is then displayed together with the position of the tracked instrument on a transparent overlay that can be put on top of the patient. An ongoing challenge with the static preoperative CT images is the reduced navigational accuracy due to respiratory motion. Strides have been made with electromagnetic tracking for abdominal interventions [87-91]. However, no system exists today that can compensate for lung motion around lung tumours.

Recent advances in electromagnetic tracking systems have led to the miniaturization of the sensors and better immunity to nearby metallic objects. For example, the microBIRD™ tracking system (Ascension Technology Corporation) features a 6 degree-of-freedom DC magnetic tracker with a sensor diameter of just 1.3 mm. An electromagnetic transmitter situated outside of the body generates a weak spatially varying magnetic field that can be measured by the sensor to dynamically compute position and orientation. Field distortions caused by nearby conductive metals, which significantly affected earlier AC systems, have been minimized using DC pulses.

**Brachytherapy Treatment Planning**

CT simulation has been the standard for treatment planning in many modern radiation therapy centres; however, CT simulation is not readily available intraoperatively in most countries. The literature on 3D ultrasound simulation with permanent brachytherapy seed implantation treatment planning in lung cancer is limited [92]. The number of permanent seeds used in a given tumour volume and the angle of brachytherapy needle entry for a given tumour mass have yet to be defined. The dosimetry plan for MIS interstitial brachytherapy seeds in lung tumours is unknown. Standard needle templates used in prostate brachytherapy are not usable for intrathoracic tumours due to the bony rib cage and the restriction of only one entry port as a component of MIS. New approaches need to be developed.

**Brachytherapy Seed Delivery System**

Many researchers have been working on ways to improve brachytherapy procedures. Currently the most common usage of brachytherapy is in the treatment of prostate cancer and hence many of the developments have focused on this area. The contributions found in the literature can be summarized as follows: control of the relative motion between the hollow needle and the plunger [93]; accurate positioning and orienting of the needle prior to penetration [94-96]; drivers for needle penetration [37, 96, 97]; real-time image guidance during needle insertion [85, 94-98]; force feedback during needle insertion [96-99]; and tissue motion compensation [100-103]. However, none of these devices is currently available on the market due to their complexity and lack of regulatory approval for clinical use. Additionally, they are designed only for percutaneous needle insertion, and most have been designed specifically to treat tumours located in the prostate. The process of implanting seeds within lung cancerous tissue could greatly benefit from the use of minimally invasive robotic systems; however, an instrument that can be attached to these systems for brachytherapy is not currently available.

We shall describe some of the pioneer work at Canadian Surgical Technologies and Advanced Robotics (CSTAR) on Robotics-Assisted Brachytherapy for the potential future management of lung cancer.

**SYSTEM AT CSTAR**

Our work at CSTAR has focused on six areas: i) development of a lung tumour model and robotic brachytherapy test bed; ii) development of 3D ultrasound imaging for lung tumours; iii) design of a delivery system for robotic brachytherapy; iv) robotics-assisted brachytherapy using the ZEUS platform; v) development of an electromagnetic navigation system for precise needle insertion; and vi) dosimetry planning.

An experimental test bed was developed to assess the feasibility of robotics-assisted minimally invasive lung brachytherapy when compared to other more traditional methods [104-106] (Fig. 2). The system consists of a Video Assisted Thoracic Surgery (VATS) box, surgical robotic arms, a customized seed injector, an ultrasound machine, an electromagnetic tracking system, video monitors, a computer, and an endoscope. The ZEUS surgical system consists of two arms for instruments. The endoscopic camera is held by the AESOP robotic endoscope holder. All three arms can be teleoperated by the surgeon from a computer-based remote console. The instrument arms mimic the motion of hand-held instruments, which are manipulated by the surgeon from the remote console. Control systems were designed for the ZEUS arms that replaced the existing controllers in order to provide more accurate and versatile control of the motions of the two arms. One of the arms can be used to hold and manipulate the ultrasound probe, and another to hold and position the seed injector [107].

In this setup, the Aurora electromagnetic tracking system (Northern Digital Inc.) was used to track the location of the needle and the ultrasound probe. The tiny sensors available as part of the Aurora system allowed the placement of the sensor at the tip of the stylet inside the needle [106].

In order to use the robotic system to deposit radioactive seeds inside a lung tumour within a minimally invasive environment when the target tumour is located within the lung and thus is not visible, we developed the InterNav3.0™ software environment [108]. It incorporates the ultrasound image, the information from the electromagnetic sensors, and calibration data to provide the user with enough information to accurately guide and position a needle at a desired target. A Graphical User Interface (GUI) was developed as a front end for the InterNav3.0 application. The InterNav3.0 GUI consists of several views that provide a wealth of information and functionality. Not only does the GUI allow the user to visualize the anatomical area of interest, it also allows the user to select the appropriate target, and provide all of the information required to guide the needle towards the target in a quick and intuitive manner (Fig. 3).
The robotic arm carrying the seed injector allows the position and orientation of the needle to be adjusted inside the patient’s body prior to penetrating the target tissue. The MIS approach allows better access to organs inside the thoracic cavity, and therefore can safely avoid vital structures. The injector can easily penetrate the more scirrhous tumours, and the remote actuation of the needle retraction system reduces the exposure of the clinician to the radiation source.

A technique for creating intraoperative, near real time, 3D ultrasound images of human lung nodules using MIS techniques was developed [109]. Multiple 2D ultrasound images of a subpleural nodule scanned intraoperatively were reconstructed into 3D images. We adapted the HDI 5000 LapL9-5 laparoscopic probe to a transducer holder containing a mechanical motor attached to a standard computer. The modified probe was used to thoracoscopically detect and remove a subpleural nodule through three 12 mm incisions. The device was easy to use and the images accurately identified the tumour. The images correlated well with the preoperative CT scan and final pathology. Intraoperative 3D ultrasound proved to be feasible in localizing invisible or nonpalpable lung nodules in near real time and provided an accurate representation of the anatomy during thoracoscopic lung surgery. This is the world’s first example of thoracoscopic 3D ultrasound imaging of a human lung nodule (Fig. 4) [109].

An ex vivo lung tumour model, using excised porcine lung and agar tumours was developed to provide a means of verifying 3D ultrasound images and to provide a teaching tool for intraoperative lung ultrasound techniques [110, 111]. Spherical tumours of various size were made from agar and were inserted through incisions on the underside of an excised porcine lung. The average coefficient of variation and volume error during tumour localization was 11.2% and 12.9% respectively, and tumour volume error decreased as the tumour size increased [111, 112].

Our initial proof of principle experiments demonstrated that permanent interstitial brachytherapy seeds can be safely and reproducibly inserted using an MIS technique with the assistance of the ZEUS robotic system and intraoperative ultrasound into in vivo porcine lungs [113]. There were no problems with bleeding or air leaks. The ZEUS system performed well and was able to remotely manipulate the ultrasound transducer and needle to allow deployment of the seeds [114]. The ultrasound images were of good quality, and provided adequate visualization of the needle insertion and seed deployment. There was no evidence of seed embolization in the two animals during three months. These experiments showed that interstitial brachytherapy seeds can be safely inserted into lungs using the ZEUS robotic system with 2D ultrasound image guidance.

We also compared the accuracy, effort, and time needed to place seeds next to a target using a manual method (open surgery), video-assisted thoracoscopy (VATS), and the ZEUS robot [115, 116]. Our brachytherapy seed injector was mounted on the ZEUS system [107]. Four different people inserted dummy brachytherapy seeds into clear agar-gelatin cubes containing a 1.6 mm stainless steel ball serving as a visible target. As anticipated, the open surgery technique with manual needle insertion is the most accurate, least traumatic (requiring less needle punctures), and the fastest method of inserting seeds into tumours. However, the ZEUS robotics-assisted brachytherapy was less traumatic and faster than the VATS technique.

Further experimental results showed that the InterNav3.0 electromagnetic navigation system improved the performance of minimally invasive brachytherapy procedures in terms of effort and median tissue trauma, while also showing promise in improving the accuracy of seed deployment2. With manual insertions, the navigation system offered no advantage in time, although it led to a reduction of the number of attempts and an improvement in accuracy. The benefit of a guidance system was manifested only when visual information becomes limited in MIS scenarios; whereas the intuitive three-dimensional spatial perception afforded by the open manual technique has made an add-on guiding system seem unnecessary. When procedures must be done minimally invasively, however, electromagnetic guidance becomes essential. The addition of image guidance reduced the average task completion time of

---

1Pytel M, Trejos AL, Patel RV, and Malthaner RA. The InterNav electromagnetic guidance system for robotic needle insertion. 2006/1/10. Unpublished data.
one seed insertion by 60 seconds. For the robotic procedure, the average time was reduced by 30 seconds. The time saved becomes even more significant when more seeds need to be inserted.

Dosimetry planning was assessed using the Theraplan Plus® software and has been found feasible [93]. In an effort to realize real time dosimetry replanning as brachytherapy seeds are deposited, preliminary software was developed by Dr. A. Fenster’s research team. The software accounts for actual seed position and recalculates the dosimetry as more
seeds are deposited (Fig. 5). The software has been modified from a template based system for prostate implants to allow nonparallel needle insertion that would be necessary in a minimally invasive approach. *In vitro* and *ex vivo* experiments were done to test the performance of the system in terms of its ability to optimize the quality of the radiation coverage on phantom tumours.

Three-dimensional ultrasound scans of phantom agar tumours were used for preplanning seed locations. The *in vitro* PTVs covered by at least 100% the prescribed dose (V100) was about 97%; that covered by at least 90% of the prescribed dose (V90) was about 99%. The minimum dose received by 90% of the volume (D90), a parameter that is most sensitive to deviations in seed deposition, remained high at about 125 Gy (compared to preplan value of about 145 Gy). The results using *ex vivo* porcine lungs were slightly less accurate, although still acceptable in terms of potential for future therapeutic use. The lung brachytherapy system performed well in both *in vitro* and *ex vivo* lung tissue.

**LIMITATIONS AND FUTURE DIRECTIONS**

A major limitation to any electromagnetic tracking system is the possible distortion in the field by magnetic interference caused by the presence of nearby metal objects. Improvements in technology have made the current generation of sensors less susceptible to such interferences. Our experience was that modest amounts of surgical steel in the environment do not cause any noticeable deterioration of accuracy. However, it would still be important to keep the amount of metal to a minimum, and the addition of metallic shields could ensure optimal performance.

---

The accuracy of brachytherapy seed injection was limited by the intrinsic resolution of the ultrasound probe. This resolution may be somewhat improved by using a newer probe or one with higher frequency (although this would have been at the expense of penetration depth). 3D ultrasound may hold the key to improved visualization and real time dosimetry planning. A better sense of the tissue may be obtained through reconstruction of the 3D space by piecing together 2D images and their position information.

CONCLUSION

Lung cancer brachytherapy has been advocated for years. Recent advances in technology such as robotic assistance and image guidance give promise to improved performance of minimally invasive lung brachytherapy procedures, potentially expanding its clinical role and facilitating better patient outcomes. Robotic assistance enables precise manipulation of the brachytherapy needle while enhancing the ergonomics for the surgeon and radiation oncologist; real-time virtual reconstruction of the tissue of interest and image guidance allows more intuitive and reliable seed deposition. By integrating these two aspects of technology, the surgical procedure can be made more automatic, easier to learn, less susceptible to user variability, and may translate into better treatment efficacy with fewer side effects.

ACKNOWLEDGEMENT

The authors wish to thank A.W. Lin, M. Pytel, H. Bassan, and S. Mohan for their research contributions to the lung brachytherapy project.

DISCLOSURE

Part of the information included in this review has been previously published in TELESURGERY 2008, 33-52.

CONFLICT OF INTEREST

The authors have no conflicts of interest to report.

ABBREVIATIONS

2D = Two-dimensional
3D = Three-dimensional
AC = Alternating current
CAS = Computer-assisted surgical systems
CSTAR = Canadian Surgical Technologies & Advanced Robotics
CT = Computed tomography
DC = Direct current
GUI = Graphical User Interface
HDR = High dose rate
LDR = Low dose rate
MRI = Magnetic resonance imaging
MIS = Minimally invasive surgery
NSCLC = Non small cell lung cancer
PET = Positron emission tomography
US = Ultrasound
VATS = Video-assisted thoracic surgery

REFERENCES


Lung Cancer Brachytherapy


